Table 1.
COVID‐19 dermatological manifestations in Mexico
| Characteristic | Value (%) |
|---|---|
| Total | 164 |
| Sex | |
| Female | 120 (73.3) |
| Male | 44 (26.8) |
| Age (range) | |
| 31–40 | 39 (23.8) |
| 21–30 | 30 (18.3) |
| 41–50 | 28 (17.1) |
| 51–60 | 22 (13.4) |
| 11–20 | 14 (8.5) |
| 0–10 | 22 (13.4) |
| 61–70 | 6 (3.7) |
| 71–80 | 3 (1.8) |
| Anatomical site a | |
| Trunk | 49 (29.9) |
| Lower extremities | 43 (26.2) |
| Upper extremities | 33 (20.1) |
| Face | 17 (10.4) |
| Oral mucosa | 14 (8.5) |
| Palms/Soles | 14 (8.5) |
| Scalp | 10 (6.1) |
| Extensor surfaces | 9 (5.5) |
| Flexor surfaces | 7 (4.3) |
| Skin manifestation a | |
| Urticaria | 40 (24.4) |
| Maculopapular eruption | 28 (23.2) |
| Varicelliform eruption | 25 (15.2) |
| Enanthema | 13 (7.9) |
| Pernio‐like eruption | 11 (6.7) |
| Petechiae/Purpura | 10 (6.1) |
| Palmar erythema | 10 (6.1) |
| Pityriasis rosea‐like eruption | 7 (4.3) |
| Alopecia (unspecified) | 6 (3.7) |
| Elbow/knee erythema | 6 (3.7) |
| Erythema multiforme‐like eruption | 5 (3) |
| Livedo racemosa | 2 (1.2) |
| COVID‐19 diagnosis/testing | |
| PCR positive | 86 (52.4) |
| Positive antibodies | 9 (5.5) |
| Clinical diagnosis | 29 (17.7) |
| Unspecified diagnostic test | 40 (24.4) |
a
Patients may fall into more than one category.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.